![]() |
Open for inclusion |
A Phase Ib/II Randomised Open Label Study of BGB324 in Combination With Pembrolizumab or Dabrafenib Compared to Pembrolizumab or Dabrafenib Monotherapy, in Patients With Advanced Non-resectable (Stage IIIc) or Metastatic (Stage IV) MelanomaCancer type: Melanoma Phase: I/II Principal Investigator: Straume Oddbjørn Country: NO Keywords: Norway, Bergen, BGB324, metastatic melonoma Status: Open for inclusion Link to Clinicaltrials.gov: https://clinicaltrials.gov/ct2/show/NCT02872259?term=BGB&rank=6 |